MyPathway (HER2-positive biliary tract cohort)
In previously treated HER2-positive metastatic biliary tract cancer, is pertuzumab plus trastuzumab active in a molecular basket cohort?
Trial design and population
Key results
Nine of 39 patients had a partial response: ORR 23% (95% CI 11–39). Median follow-up was 8.1 months. Grade 3–4 treatment-emergent adverse events occurred in 46%.
Source-reported outcome visualization
Objective response rate · Best overall response
Bars display source-reported values for the named endpoint; where the endpoint is a median, bars compare medians and do not represent probabilities. No unreported rates are inferred.
Absolute Effect
Single-arm response rate; no comparator-based absolute benefit or NNT can be calculated.
NNT: Not applicable — single-arm cohort. No NNT is derived from median survival/PFS differences.
NNH / harm: Grade 3–4 treatment-emergent adverse events 46%, commonly elevated ALT/AST; three patients had treatment-related grade 3 events. No treatment-related deaths reported.
NNT/NNH are only displayed where the endpoint and time horizon support a defensible absolute-risk calculation. Otherwise, the source-reported outcome is visualized.
Safety and treatment burden
Grade 3–4 treatment-emergent adverse events 46%, commonly elevated ALT/AST; three patients had treatment-related grade 3 events. No treatment-related deaths reported.
Follow-up, maturity and limitations
Small non-randomized molecularly selected cohort; HER2 testing definitions and tumour heterogeneity matter. This is a basket cohort, not a dedicated randomized BTC trial.
Clinical interpretation
Current-practice context · reviewed 20 October 2026
This page separates original trial findings from contemporary treatment context. Confirm current disease-specific guidelines, local regulatory status, biomarker requirements, prior treatment exposure and patient-specific contraindications before applying the evidence. Historical comparators may no longer represent current standard practice; subgroup findings and immature endpoints should not be generalized.